Shanghai Chest Hospital, Shanghai, China Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01217619
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Baohui Han | Shanghai Chest Hospital, Shanghai, China | The Chest Hospital of Shanghai

Active Ingredients

Drugs in Phase 3 Trials (1)

osimertinib (tagrisso) (1 trial)

Drugs in Phase 2 Trials (3)

erlotinib (tarceva) (1 trial)

glumetinib (1 trial)

hs-10296 (1 trial)

Drugs in Other Trials (3)

carboplatin (paraplatin) (1 trial)

gefitinib (iressa) (1 trial)

pemetrexed (alimta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7